Haemonetics Reports 42% Net Income Drop, $86.5M Intangible Asset Impairment in FY26 Annual Report

summarizeSummary

Haemonetics reported a 42% decrease in net income and a 38.1% drop in diluted EPS for fiscal year 2026, largely due to an $86.5 million intangible asset impairment charge.

check_boxKey Events

• Significant Decline in Net Income and EPS

  Net income decreased by 42.0% to $97.3 million, and diluted EPS fell by 38.1% to $2.05 for fiscal year 2026 compared to the previous year.

• Major Intangible Asset Impairment Charge

  The company recognized an $86.5 million impairment of intangible assets in fiscal 2026, primarily affecting the Attune Medical asset group and HAS viscoelastic diagnostic devices within the Hospital business unit.

• Future Impairment Risk Identified

  The Interventional Technologies reporting unit's fair value exceeded its carrying value by only 6%, indicating a risk of future goodwill impairment if market conditions or performance deteriorate.

• Acquisition of Vivasure Medical Limited

  Haemonetics acquired Vivasure Medical for $164.4 million in January 2026, expanding its Hospital business unit portfolio in interventional cardiology.

auto_awesomeAnalysis

Haemonetics' annual report reveals a significant decline in fiscal year 2026 net income and EPS, primarily driven by an $86.5 million intangible asset impairment charge. This charge, mainly related to the Attune Medical asset group and HAS viscoelastic diagnostic devices, highlights underperformance in certain acquired assets. The Interventional Technologies reporting unit, a key part of the Hospital segment, is noted to have a fair value only 6% above its carrying value, indicating a heightened risk of future goodwill impairment. While the company completed an acquisition and continued its share repurchase program, these positive actions are overshadowed by the substantial financial underperformance and asset write-downs.